Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 795
Single User License Price INR 54553
Corporate User License Price USD 2385
Corporate User License Price INR 163659
Site License Price USD 1590
Site License Price INR 109106
Request a Quote

Report Title

Generics North America (NAFTA) Industry Guide 2017-2021

Quote Request for License Type
License Type Price  
Single User License USD 795
Site License USD 1590
Enterprise Wide License USD 2385
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Generics North America (NAFTA) Industry Guide 2017-2021


Quote Request for License Type
License Type Price  
Single User License USD 795
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Generics North America (NAFTA) Industry Guide 2017-2021

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Generics North America (NAFTA) Industry Guide 2017-2021



Executive Summary

Generics North America (NAFTA) Industry Guide 2017-2021

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of USD1,11,669.7 million in 2016.The Mexico was the fastest growing country, with a CAGR of 14.3% over the 2012-16 period.

Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of USD1,01,790.0 million in 2016. This was followed by Mexico and Canada, with a value of USD5,430.1 and USD4,449.6 million, respectively.

The US is expected to lead the generics industry in the NAFTA bloc, with a value of USD1,48,130.6 million in 2021, followed by Mexico and Canada with expected values of USD10,769.6 and USD6,409.3 million, respectively.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

What was the size of the NAFTA generics market by value in 2016?

What will be the size of the NAFTA generics market in 2021?

What factors are affecting the strength of competition in the NAFTA generics market?

How has the market performed over the last five years?

How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

NAFTA Generics

Industry Outlook

Generics in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Mexico

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United States 40

Market Overview 40

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading Companies

Appendix

Methodology

About MarketLine

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Figure 1: NAFTA countries generics industry, revenue (USDm), 2012-21

Figure 2: NAFTA countries generics industry, revenue (USDm), 2012-16

Figure 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21

Figure 4: Canada generics market value: USD million, 2012-16

Figure 5: Canada generics market volume: % of total pharma volume, 2012-16

Figure 6: Canada generics market geography segmentation: % share, by value, 2016

Figure 7: Canada generics market value forecast: USD million, 2016-21

Figure 8: Canada generics market volume forecast: % of total pharma volume, 2016-21

Figure 9: Forces driving competition in the generics market in Canada, 2016

Figure 10: Drivers of buyer power in the generics market in Canada, 2016

Figure 11: Drivers of supplier power in the generics market in Canada, 2016

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 15: Mexico generics market value: USD million, 2012-16

Figure 16: Mexico generics market volume: % of total pharma volume, 2012-16

Figure 17: Mexico generics market geography segmentation: % share, by value, 2016

Figure 18: Mexico generics market value forecast: USD million, 2016-21

Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Figure 20: Forces driving competition in the generics market in Mexico, 2016

Figure 21: Drivers of buyer power in the generics market in Mexico, 2016

Figure 22: Drivers of supplier power in the generics market in Mexico, 2016

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016

Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2016

Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2016

Figure 26: United States generics market value: USD billion, 2012-16

Figure 27: United States generics market volume: % of total pharma volume, 2012-16

Figure 28: United States generics market geography segmentation: % share, by value, 2016

Figure 29: United States generics market value forecast: USD billion, 2016-21

Figure 30: United States generics market volume forecast: % of total pharma volume, 2016-21

Figure 31: Forces driving competition in the generics market in the United States, 2016

Figure 32: Drivers of buyer power in the generics market in the United States, 2016

Figure 33: Drivers of supplier power in the generics market in the United States, 2016

Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 37: Mylan N.V.: revenues & profitability

Figure 38: Mylan N.V.: assets & liabilities

Figure 39: Novartis AG: revenues & profitability

Figure 40: Novartis AG: assets & liabilities

Figure 41: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 42: Teva Pharmaceutical Industries Limited: assets & liabilities

List of Tables

Table 1: NAFTA countries generics industry, revenue (USDm), 2012-21

Table 2: NAFTA countries generics industry, revenue (USDm), 2012-16

Table 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21

Table 4: Canada generics market value: USD million, 2012-16

Table 5: Canada generics market volume: % of total pharma volume, 2012-16

Table 6: Canada generics market geography segmentation: USD million, 2016

Table 7: Canada generics market value forecast: USD million, 2016-21

Table 8: Canada generics market volume forecast: % of total pharma volume, 2016-21

Table 31: Canada size of population (million), 2012-16

Table 32: Canada gdp (constant 2005 prices, USD billion), 2012-16

Table 33: Canada gdp (current prices, USD billion), 2012-16

Table 34: Canada inflation, 2012-16

Table 35: Canada consumer price index (absolute), 2012-16

Table 36: Canada exchange rate, 2012-16

Table 9: Mexico generics market value: USD million, 2012-16

Table 10: Mexico generics market volume: % of total pharma volume, 2012-16

Table 11: Mexico generics market geography segmentation: USD million, 2016

Table 12: Mexico generics market value forecast: USD million, 2016-21

Table 13: Mexico generics market volume forecast: % of total pharma volume, 2016-21

Table 14: Mexico size of population (million), 2012-16

Table 15: Mexico gdp (constant 2005 prices, USD billion), 2012-16

Table 16: Mexico gdp (current prices, USD billion), 2012-16

Table 17: Mexico inflation, 2012-16

Table 18: Mexico consumer price index (absolute), 2012-16

Table 19: Mexico exchange rate, 2012-16

Table 20: United States generics market value: USD billion, 2012-16

Table 21: United States generics market volume: % of total pharma volume, 2012-16

Table 22: United States generics market geography segmentation: USD billion, 2016

Table 23: United States generics market value forecast: USD billion, 2016-21

Table 24: United States generics market volume forecast: % of total pharma volume, 2016-21

Table 25: United States size of population (million), 2012-16

Table 26: United States gdp (constant 2005 prices, USD billion), 2012-16

Table 27: United States gdp (current prices, USD billion), 2012-16

Table 28: United States inflation, 2012-16

Table 29: United States consumer price index (absolute), 2012-16

Table 30: United States exchange rate, 2012-15

Table 37: Apotex, Inc.: key facts

Table 38: Mylan N.V.: key facts

Table 39: Mylan N.V.: key financials (USD)

Table 40: Mylan N.V.: key financial ratios

Table 41: Novartis AG: key facts

Table 42: Novartis AG: key financials (USD)

Table 43: Novartis AG: key financial ratios

Table 44: Teva Pharmaceutical Industries Limited: key facts

Table 45: Teva Pharmaceutical Industries Limited: key financials (USD)

Table 46: Teva Pharmaceutical Industries Limited: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person